OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.
to win the war against cancer
IR News22/12/2021Announcement of the press release from QST regarding the publication of 225Ac-labeled OTSA101
IR News01/10/2021Poster presentation of OTSA101 research for cervical cancer at the 80th Annual Meeting of the Japanese Cancer Association
Business News10/03/2021Publication of a paper describing the synergistic effect of OTS167 and FLT3 inhibitors on acute myeloid leukemia
Our service offers comprehensive analysis of TCR repertoire from blood and tissue samples using next generation sequencing technology. A detailed data analysis will be performed. We ensure that we will perform this service consistently, from sample preparation to delivering results.
and Safer Cancer Treatments
Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.